Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM-BCP-01 in Mild to Moderate COVID-19
NCT05429021Phase 1Terminated
- Sponsor
- Immunome
- Start
- Jun 2022
- Primary completion
- Jan 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IMM-BCP-01 in coronavirus disease 2019 (COVID-19) (4 cohorts), sponsored by Immunome. Primary endpoint: Treatment Emergent Adverse Events at 28 days. Started Jun 2022; status: terminated.
02
Drugs
IMM-BCP-01
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05429021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429021.